Somewhat Positive News Coverage Somewhat Unlikely to Affect Mesa Laboratories (MLAB) Stock Price

News stories about Mesa Laboratories (NASDAQ:MLAB) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mesa Laboratories earned a news impact score of 0.04 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.2841850904773 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Several research analysts recently commented on MLAB shares. BidaskClub upgraded shares of Mesa Laboratories from a “sell” rating to a “hold” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, TheStreet downgraded shares of Mesa Laboratories from a “b-” rating to a “c” rating in a report on Wednesday, February 7th.

Mesa Laboratories (NASDAQ:MLAB) traded up $1.45 during trading hours on Friday, hitting $138.96. 11,300 shares of the stock traded hands, compared to its average volume of 17,590. Mesa Laboratories has a one year low of $117.58 and a one year high of $169.80. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.64 and a current ratio of 2.37. The company has a market cap of $520.22, a P/E ratio of 58.51 and a beta of 0.52.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Wednesday, February 28th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $0.64 annualized dividend and a dividend yield of 0.46%. Mesa Laboratories’s payout ratio is -64.00%.

In other news, Director John Bradley Schmieder sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the director now directly owns 77,869 shares in the company, valued at $10,299,732.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John James Sullivan sold 4,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $138.00, for a total transaction of $552,000.00. Following the completion of the transaction, the director now owns 72,248 shares in the company, valued at $9,970,224. The disclosure for this sale can be found here. Insiders own 15.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2018/02/23/mesa-laboratories-mlab-given-daily-news-impact-score-of-0-04.html.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply